Gilead 2Q Revenues: $5.6 billion (-21%) 2Q Earnings: $1.8 billion (-41%) YTD Revenues: $10.7 billion (-21%) YTD Earnings: $3.4 billion (-42%) Comments: HIV product sales were $3.7 billion in the quarter up 16%, primarily due to continued uptake of Biktarvy and Descovy, Genvoya, and Odefsey. Chronic hepatitis C (HCV) product sales, which consist of Epclusa, Harvoni, Vosevi, and Sovaldi, were $1.0 billion in the quarter, down 66%. The decline was primarily due to lower sales of Harvoni, Epclu...